FRI0491 MANAGEMENT OF SECONDARY OSTEOPOROSIS FRACTURES IN FRACTURE LIAISON SERVICE OF REIMS HOSPITAL IN FRANCE: STUDY AT 25 MONTHS OF FOLLOW-UP
Authors: HITTINGER Ambre, Jean-Hugues Salmon, Jean Paul Eschard, Isabelle Charlot-Lambrecht
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Osteoporosis is a major public health issue, progressing with the aging of the population and responsible for nearly 400,000 fractures/year in France. Fracture Liaison Services (FLS) are systems of detection and secondary prevention of osteoporotic fractures. These systems are recognized as effective by international scientific societies. <h3>Objectives</h3> The aim of this study was to evaluate the efficiency of Reims Hospital FLS protocol after 25 months of implementation. <h3>Methods</h3> We performed an ambispective monocentric observational study at the Reims Hospital between April 2016 and May 2018. We included patients over 50 years who were hospitalized in the orthopedic department for osteoporotic fractures. These patients were evaluated clinically, biologically and radiographically during a one-day hospitalization in the rheumatology unit. Therapeutic compliance and fracture recurrence were assessed in consultation at 3-month and 1-year telephone interviews. <h3>Results</h3> Sixty-four/242 patients (26.4%) identified in orthopedic service were included. The average age was 72 years old with a sex ratio of 1:10. The most common fracture was the proximal end of the femur for 25 patients (39%). Fifty-five patients (85.9%) had an indication for osteoporosis treatment, the most prescribed was zoledronic acid for 45 patients (81.9%). Twenty-four/55 patients (43.6%) started their treatment and 22/24 (91.7%) were still treated at one year. One patient (1.63%) died within the follow-up period. Twelve/55 patients (21.8%) presented a new fall and 7/55 patients (12.7%) experienced a new fracture. Comparative analysis of observant versus non-observant population groups at 1 year showed that non-observant patients had significantly more recurrent falls (93.54% versus 68.18%, p = 0.024) and received treatment of zoledronic acid (93.56% versus 63.64%, p = 0.010). Further analysis showed that our low rate of initiation treatment was due to difficulties in implementing bisphosphonates, mainly because of the dental care needed. However, we observed a high rate of treatment adhesion at 1 year, once the treatment is started. During this study, we identified 2 areas of improvement: therapeutic education to improve patient adherence and fall risk factors to decrease recurrent fall rate. <h3>Conclusion</h3> There is a real benefit to the establishment of this FLS with a high rate of therapeutic compliance at 1 year follow-up. However there are opportunities for improvements in treatment initiation through patients therapeutic education. <h3>References</h3> [1] Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. mai 2017;76(5):802–10. <h3>Disclosure of Interests</h3> Ambre HITTINGER: None declared, Jean-Hugues Salmon Speakers bureau: Janssen Novartis, jean paul eschard: None declared, Isabelle CHARLOT-LAMBRECHT: None declared